BLRX
BioLineRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BLRX
Biolinerx Ltd.
A late clinical-stage biopharmaceutical company focused on oncology
Biological Technology
--
07/25/2011
NASDAQ Stock Exchange
24
12-31
Depository Receipts (Ordinary Shares)
2 HaMa’ayan Street, Modi’in 7177871, Israel
Late-stage clinical-stage biopharmaceutical companies.
BioLineRx Ltd. Incorporated and commenced business in April 2003, it is a clinical-stage biopharmaceutical development company. The company is committed to identifying, licensing and developing drug candidates that have advantages over existing available treatments or that can address medical needs. The current development pipeline includes six clinical stage therapeutic candidates: BL -1040, a novel polymer solution for the prevention of ventricular remodeling after acute myocardial infarction, or AMI; BL -8040, a novel peptide for the treatment of acute myeloid leukemia (AML), stem cell mobilization and hematological indications; BL -7010, a novel polymer for the treatment of celiac disease; BL -5010, A customized, proprietary pen applicator containing a novel formulation of two acids is being developed in Europe as a medical device for non-surgical resection of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease, or IBD; and BL-8020, an oral drug for the treatment of hepatitis C virus (HCV) and viral indications, with a unique mechanism of action involving the inhibition of virus-induced autophagy in host cells.
Earnings Call
Q1/2025
Estimate EPS-1.06
Actual EPS0
Estimate Revenue1.48M
Actual Revenue255.00K
BioLineRx's Q1 2025: Unpacking Contradictions in Cash Runway, Regulatory Strategy, and APHEXDA Market Potential
May 27,2025 01:03
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.53
Actual EPS0
Estimate Revenue661.33K
Actual Revenue304.00K
Regeneron's 2025 Q2 Earnings Call: Unraveling Key Contradictions on Study Rights, Communication, and Margins
Aug 14,2025 10:54
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BLRX has released its 2024 Q3 earnings. EPS was reported at -0.02, versus the expected -0.11, beating expectations. The chart below visualizes how BLRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BLRX has released its 2025 Q3 earnings report, with revenue of 427.00K, reflecting a YoY change of -91.36%, and net profit of -977.00K, showing a YoY change of 83.22%. The Sankey diagram below clearly presents BLRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
